Stock A009420 HANALL BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 17/05/2024 am IST 		5-day change 1st Jan Change
37,300 KRW +2.05% Intraday chart for Hanall Biopharma Co., Ltd. +9.06% -15.80%
03/05 HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease CI
06/03 Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.

Number of employees: 306

Sales per Business

KRW in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
109,995 100.0 % 134,910 100.0 % +22.65%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
99.9 %
109,960 100.0 % 134,839 99.9 % +22.63%
International
0.1 %
36 0.0 % 71 0.1 % +97.61%

Managers

Managers TitleAgeSince
Su-jin Park CEO
 Chief Executive Officer - 29/23/29
Seung-Kook Park CEO
 Chief Executive Officer 61 -
Seung-Won Jeong BRD
 Director/Board Member 53 01/21/01
Sung-Yeon Im BRD
 Director/Board Member 55 -
Beom-Kyu Son PRN
 Corporate Officer/Principal 56 -

Members of the board

Members of the board TitleAgeSince
Jae-Chun Yoon BRD
 Director/Board Member 64 30/15/30
Seung-Kook Park CEO
 Chief Executive Officer 61 -
Sung-Yeon Im BRD
 Director/Board Member 55 -
Jin-Hyoung Kim BRD
 Director/Board Member 47 18/16/18
Cheol-Heon Lee BRD
 Director/Board Member 50 -
Jung-Kyu Lee BRD
 Director/Board Member 61 -
Heon Jeong BRD
 Director/Board Member 48 -
Seung-Won Jeong BRD
 Director/Board Member 53 01/21/01
Almira Chabi BRD
 Director/Board Member - 24/11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,240,638 30,678,163 ( 58.72 %) 1,544,521 ( 2.957 %) 58.72 %

Shareholders

NameEquities%Valuation
DAEWOONG PHARMACEUTICAL CO., LTD
30.85 %
16,115,745 30.85 % 421 M ₩
National Pension Service of Korea
11.71 %
6,115,313 11.71 % 160 M ₩
Hong-Cheol Kim
4.483 %
2,342,000 4.483 % 61 M ₩
HANALL BIOPHARMA CO., LTD.
2.962 %
1,547,521 2.962 % 40 M ₩
Sung-Wuk Kim
2.813 %
1,469,702 2.813 % 38 M ₩
Seung-Kook Park
0.1315 %
68,697 0.1315 % 2 M ₩
Seung-Won Jeong
0.0252 %
13,187 0.0252 % 344 440 ₩
An Hye-kyung
0.0149 %
7,780 0.0149 % 203 211 ₩
DFA Australia Ltd.
0.009119 %
4,764 0.009119 % 124 434 ₩
NH-Amundi Asset Management Co., Ltd.
0.005411 %
2,827 0.005411 % 73 840 ₩

Holdings

NameEquities%Valuation
HANALL BIOPHARMA CO., LTD.
2.96%
 1,547,521 2.96% 40,420,738 $

Company contact information

HANALL BIOPHARMA Co., Ltd.

43 Sangseodang 1-gil Daedeok-gu

34344, Daejeon

+

http://www.hanall.co.kr
address Hanall Biopharma Co., Ltd.(A009420)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Hanall Biopharma Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37,300 KRW
Average target price
43,600 KRW
Spread / Average Target
+16.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HANALL BIOPHARMA CO., LTD. Stock Hanall Biopharma Co., Ltd.
-15.80% 137.55Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 69TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 59TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 37TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+7.39% 29TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 21TCr
NOVARTIS AG Stock Novartis AG
+10.02% 21TCr
AMGEN INC. Stock Amgen Inc.
+8.49% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A009420 Stock
  4. Company Hanall Biopharma Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW